Category: Uncategorized

Agreement spans wide range of Medidata’s solutions to enhance clinical trial efficiency

NEW YORK, Feb 29 (Bernama-BUSINESS WIRE) — Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced it has renewed its relationship with the PPD clinical research business of Thermo Fisher Scientific Inc.

The agreement features the Medidata Platform, as well as Medidata Adjudicate and additional Medidata Rave product offerings that support the PPD clinical research business in advancing its customers’ drug development programs.

A key element of this relationship is the evolution of PPD TrueCast, a business solution powered by Medidata AI that shortens study timelines by combining patient recruitment and site performance data to deliver powerful predictive models and advanced analytics.

“Over the past 15 years, we have built a valued connection with the PPD clinical research business to enhance visibility and decision-making during clinical trials,” said Janet Butler, executive vice president and head of global sales, Medidata. “We look forward to working together to complete studies faster, boost drug development productivity, and ultimately bring life-changing treatments to patients sooner.”

Medidata has collaborated with the PPD clinical research business since 2009 on more than 1,000 clinical studies for biopharmaceutical and medical device companies across a broad range of therapeutic areas from oncology to vaccines.

About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 32,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE^® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all–consumers, patients, and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20240228873753/en/

Contact

Medidata PR
Medidata.PR@3ds.com

Analyst Relations
Medidata.AR@3ds.com

Source : Medidata

–BERNAMA

KUALA LUMPUR, Feb 27 (Bernama) — European residence and citizenship by investment programmes continue to dominate the top spots of global wealth advisory firm Henley & Partners’ annual rankings of the most sought-after investment migration programmes in the world.

Malta holds onto first place in the 2024 Global Citizenship Program Index as it has done for nine consecutive years, while the Portugal Golden Residence Permit Program retains top spot on the Global Residence Program Index.

The two indexes offer a systematic analysis and comprehensive benchmarking of the world’s most attractive residence and citizenship by investment programmes, providing the gold standard in the sector.

According to Henley & Partners in a statement, the Global Citizenship Program Index ranks 13 programmes, with the strategically-located European nation of Malta scoring 77 out of 100, taking top honours once again.

Retaining second place with a score of 74 is Austria’s premium citizenship by investment offering, which requires applicants to make a substantial contribution to the Austrian economy.

Meanwhile, Europe also prevails in the 2024 Global Residence Program Index, with programmes on the continent occupying the top five positions, with the Portugal Golden Residence Permit Program ranks first overall out of 26 programmes scoring 75 out of 100.

Last year, United States-Americans were the top nationality applying for alternative residence and citizenship options via Henley & Partners, and this trend has continued into the first quarter this year.

This year’s edition includes a total of 39 programmes, representing the most relevant of over 100 programmes worldwide, which have been appraised by a panel of independent experts.

Interactive digital comparisons of the programmes are also available, enabling global investors and wealthy families to select what matters most to them when weighing up their options.

— BERNAMA

Participants include 200+ globally renowned scientists, researchers and professors in advanced materials sciences

RAS AL KHAIMAH, United Arab Emirates, Feb 23 (Bernama-BUSINESS WIRE) — Today, the 15^th International Workshop on Advanced Materials (IWAM) organised by the Ras Al Khaimah Center for Advanced Materials (RAKCAM) kicks off at the Mövenpick Resort on Al Marjan Island.

The 15^th IWAM brings together 200+ prominent scientists, professors, researchers and students from internationally acclaimed educational institutions, and over 100 attendees from UAE-based universities to discuss how advanced materials can shape the future. The event is again being held under the patronage of His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, who is participating in a fireside discussion about the importance of advanced materials in solving the world’s greatest challenges.

Advanced materials are found in mobile phones, electronics, energy systems and they include metals, ceramics and polymers, which are either new or enhanced beyond their original state. Innovations in these advanced materials have the potential to revolutionize many industries, including aerospace, transport, construction and healthcare, allowing these sectors to reduce their carbon footprint and energy use.

IWAM will welcome renowned advanced materials scientists from institutions including the University of Cambridge, University of Oxford, University of New South Wales, and the Max Planck Institute, as well as a Nobel Prize-winning professor from the University of Manchester.

As part of IWAM’s remit to involve young people in science, over 500 students from schools and universities in Ras Al Khaimah have taken part in the ‘Innovation and Sustainability Challenge’, calling on them to create innovative solutions to global challenges. Winners of this challenge and the annual prestigious Sheikh Saud International Prize for Materials Science (which offers a US$100,000 reward) will be announced later this week.

Sir Anthony Cheetham, Chairman of Ras Al Khaimah Center for Advanced Materials, commented: “His Highness Sheikh Saud is dedicated to leveraging education and science as drivers of innovations that contribute to humanity’s advancement – and committed to advancing the field of materials science. IWAM plays a vital role in this vision, inspiring young people to be a part of building a sustainable future for Ras Al Khaimah and beyond, and helping to shape a bright future for generations to come.”

More information about IWAM can be found here.

*Source: AETOSWire

View source version on businesswire.com: 
https://www.businesswire.com/news/home/53897910/en

Contacts
Steven McCombe
Media@rakmediaoffice.ae

Source: Ras Al Khaimah Government Media Office

–BERNAMA

Embark on a Journey of Cutting-Edge Treatments and Research Collaboration

KUALA LUMPUR, Malaysia, Feb 22 (Bernama-GLOBE NEWSWIRE) — As the world marks Cancer Awareness Month, Malaysia has made significant strides in the field of cancer treatment, earning recognition as a premier destination for individuals seeking advanced care. With its state-of-the-art medical facilities, renowned healthcare professionals, and commitment to innovative care, Malaysia has emerged as a beacon of hope for patients battling cancer.

In recent years, Malaysia has experienced a significant increase in medical tourism, particularly in the field of cancer treatment. According to the Malaysia Healthcare Travel Council (MHTC), the country welcomed over 1.3 million medical tourists in 2023, with a substantial number seeking cancer-related care^¹. This surge underscores Malaysia’s growing reputation as a leading destination for individuals seeking effective and affordable cancer treatment options.

Malaysia has garnered international recognition for its excellence in cancer care and treatment. The country’s healthcare system boasts advanced medical infrastructure, including internationally accredited hospitals and specialised cancer centres equipped with cutting-edge technology. These facilities offer a comprehensive range of cancer treatments, including chemotherapy, radiation therapy, immunotherapy, and surgical interventions, tailored to meet the unique needs of each patient.

At the heart of Malaysia’s appeal is the expertise of its healthcare professionals. Oncologists, surgeons, nurses, and support staff undergo rigorous training and accreditation, ensuring that patients receive top-notch treatment and personalised care throughout their cancer journey. This dedication to excellence has earned Malaysia recognition as a hub for advanced cancer treatment in the region.

Cost-effectiveness is another compelling factor driving individuals to choose Malaysia for cancer treatment. The relatively lower cost of medical procedures, combined with competitive pricing for accommodation and transportation, makes Malaysia an attractive option for patients seeking high-quality care without financial burden. Beyond medical treatment, Malaysia prioritises the holistic well-being of cancer patients, offering comprehensive support services to address their physical, emotional, and psychological needs.

Safety and accessibility are paramount considerations for patients traveling abroad for medical treatment, and Malaysia excels in both aspects. The country’s stable political environment, modern transportation infrastructure, and welcoming hospitality ensures a safe and seamless experience for international patients seeking cancer treatment.

Malaysia’s commitment to combating cancer is exemplified by the establishment of its first National Cancer Institute in 2013. This milestone marked a significant advancement in the country’s efforts to provide comprehensive cancer care, further solidifying Malaysia’s position as a leader in the field of oncology.

To further bolster its position as a global hub for cancer treatment, Malaysia continues to invest in research and development, fostering collaborations with renowned institutions worldwide. These efforts aim to drive innovation, improve treatment protocols, and ultimately contribute to the global fight against cancer.

As Cancer Awareness Month unfolds, Malaysia stands tall as a beacon of hope for patients battling this devastating disease. With its state-of-the-art infrastructure, skilled medical professionals, affordability, and commitment to advancing cancer care, Malaysia offers a compelling destination for individuals seeking effective cancer treatment options.

For more information on Malaysia Healthcare and its services, please visit https://malaysiahealthcare.org/ or visit our social feeds at: http://www.facebook.com/MHTCMalaysia or at LinkedIn (Malaysia Healthcare Travel Council).

For media enquiries:

Chandrika Bhaskaran
Senior Manager, Public Relations and Content Communications
Malaysia Healthcare Travel Council
chandrika.b@mhtc.org.my

Falliq Effendy
Manager, Public Relations and Content Communications
Malaysia Healthcare Travel Council
m.falliq@mhtc.org.my

ABOUT THE MALAYSIA HEALTHCARE TRAVEL COUNCIL

The Malaysia Healthcare Travel Council (MHTC) is a government agency under the Ministry of Health Malaysia that has been entrusted with the responsibility of facilitating and promoting the country’s healthcare travel industry, recognised as a key export service sector for the country. Founded in 2009, MHTC works to streamline industry players and service providers in facilitating and growing Malaysia’s healthcare travel industry under the brand “Malaysia Healthcare” with the intended goal of making Malaysia the leading global healthcare destination. MHTC works closely with over 90 private healthcare facilities in Malaysia, who are registered members of MHTC.
^{___________________________________
¹} MHTC Informatics 

Source: Malaysia Healthcare Travel Council

–BERNAMA

KUALA LUMPUR, Feb 21 (Bernama) — Fortrea has announced the opening of its expanded non-commercial specialty pharmacy, FortreaRx, in Lake Mary, Florida, which offers advanced patient access solutions across the United States (US), including ambient and cold-chain distribution capabilities and expertise.

Fortrea vice president and global head of Patient Access, Bill Nolan in a statement said: “Fortrea’s well-established patient services offerings, combined with the expanded capabilities of FortreaRx, deliver an end-to-end approach, from early clinical stages to post-market delivery, ensuring a comprehensive and personalised experience for patients.”

Licenced in all 50 states and US territories, FortreaRx delivers flexible, scalable solutions that meet the specific needs of its customers while providing medications to patients who may otherwise not have access to them.

Non-commercial specialty pharmacies, such as FortreaRx, provide these solutions on behalf of their pharmaceutical manufacturer customers and are uniquely positioned to serve as a bridge between pharmaceutical manufacturers and patients who meet the manufacturer requirements for prescription assistance.

Since FortreaRx’s inception in late 2008, Fortrea has pioneered non-commercial specialty pharmacy services, focusing exclusively on the distribution of free-goods products as an integrated component of pharmaceutical manufacturer-sponsored patient assistance programmes (PAP) designed to expand access to therapy for qualified patients with no health insurance or those who are underinsured.

FortreaRx’s call centre hub of case managers seamlessly manages patient inquiries, counselling and data verification of prescriptions, in which Fortrea’s patient access team helps patients and providers understand and navigate the complexities of coverage while removing obstacles to get medication to patients.

FortreaRx delivers efficient, consultative and cost-effective solutions for manufacturer prescription programmes typically resulting in significant yearly savings for patients.

A global contract research organisation, providing clinical development and patient access solutions to the life sciences industry, Fortrea partners with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need.

— BERNAMA